VEEV240816P180000
- 2.60
- +1.58+154.90%
Veeva Systems Newsroom
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
Une Sensibilisation Scientifique Ciblée Avant La Mise Sur Le Marché Permet D'accélérer De 40 % L'adoption Du Traitement
Veeva Vault Quality Permet À Neuraxpharm De Mettre En Place Des Opérations De Qualité Transparentes Et De Collaborer Avec Plus De 100 CDMO (Organisation De Développement Et De Fabrication Sous Contrat)
Here's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years
La Divulgación Científica Dirigida Antes Del Lanzamiento Acelera Un 40% La Adopción Del Tratamiento
Veeva Vault Quality Ayuda a Neuraxpharm a Impulsar Operaciones De Calidad Fluidas
Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption
Veeva Vault Quality Helps Neuraxpharm Drive Seamless Quality Operations and Collaboration With Over 100 CDMOs
Veeva Systems (VEEV) Stock Moves -1.32%: What You Should Know
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
With 82% Ownership of the Shares, Veeva Systems Inc. (NYSE:VEEV) Is Heavily Dominated by Institutional Owners
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note
Is Veeva Systems (VEEV) a Good Investment Choice?
Guggenheim Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $233
Express News | Veeva Systems Inc : Guggenheim Raises Target Price to $233 From $211
Buy Rating Affirmed: Strategic CFO Appointment and Solid Financial Outlook at Veeva Systems
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Veeva Systems (VEEV) and Arrowhead Pharmaceuticals (ARWR)
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Maintains Target Price $173
Barclays Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $220
Truist Financial Maintains Veeva Systems(VEEV.US) With Hold Rating